主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
HUMA
#3068
Humacyte, Inc. Common Stock
1.1
2
-6.67%
版块:
基础:
利润货币:
日范围
年范围
日变化
-6.67%
每月变动
+7.69%
6个月变化
-28.66%
年变化
-66.06%
前一天收盘价
1.2
0
Open
1.1
2
Bid
Ask
Low
1.1
2
High
1.1
2
交易量
61
市场
股票
医疗保健
HUMA
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
12.86 M
103 M
103.33 M
119.08 M
155.12 M
—
Valuation ratios
Enterprise value
—
529.28 M
68.25 M
263.7 M
738.41 M
1.54 B
Price to earnings ratio
—
-10.98
-17.58
-2.7
-4.01
-18.69
Price to sales ratio
—
222.91
138.94
—
149.58 K
—
Price to cash flow ratio
—
3.57
3.06
4.08
6.1
13.08
Price to book ratio
—
2.37
1.86
22.06
11.36
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
0.09
0.06
0.86
1.08
0.86
Return on equity %
—
0.22
0.1
8.18
2.82
14.46
Return on invested capital %
—
406.93
562.3
737.13
646.28
477.43
Gross margin %
—
100
100
—
100
—
Operating margin %
—
6 246.77
5 405.75
—
2.86 M
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
2 038.46
764.54
—
3.72 M
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.02
20.75
7.88
4.52
2.4
10.15
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
0.01
0.01
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.1
0.1
0.3
0.46
1.53
Long term debt to total equity ratio
—
0.22
0.17
2.85
1.2
23.11
Per share metrics
Operating cash flow per share
—
2.03
0.69
0.71
0.83
0.76
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
5.64
1.47
0.78
0.38
1.22
Net current asset value per share
—
5.74
1.5
0.81
0.4
1.56
Tangible book value per share
—
3.06
1.13
0.13
0.44
0.77
Working capital per share
—
5.46
1.31
0.63
0.24
0.94
Book value per share
—
3.06
1.13
0.13
0.44
0.77
新闻
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
BTIG重申Humacyte股票买入评级,关注国防部资金消息
BTIG reiterates Buy rating on Humacyte stock amid DoD funding news
Humacyte股价在获得国防部血管修复技术资金后跳升
Humacyte stock jumps after securing DoD funding for vascular repair tech
国防部在2026年预算中为生物工程血管修复技术拨款
DoD allocates funds for bioengineered vascular repair tech in 2026 budget
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider
基准下调Humacyte股票目标价至10美元,因以色列申请计划
Benchmark lowers Humacyte stock price target to $10 on Israel filing plans
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Humacyte plans to seek approval for vessel product in Israel